INTRODUCTION
According to the International Diabetes Federation (IDF) Diabetes Atlas, in 2011 India is already home to 61.3 million diabetes subjects and this number is predicted to reach 101.2 million by 2030. [1] Diabetes complications are looming large and 65% of the reported deaths are due to the cardiovascular complications. [2] Diabetes also confers an increased risk of developing and dying from infectious diseases and it is now considered an important complication of diabetes. [3] Indeed, the morbidity and mortality associated with infectious diseases like infl uenza and pneumonia, which are preventable by appropriate vaccination, are also very high. Although people of all ages are prone to infectious diseases like pneumonia and infl uenza, extremes of age and certain underlying medical conditions such as diabetes, asthma, and cardiovascular disease (CVD) aggravate the risk. [4] Recommendations for vaccines assume great signifi cance due to the increased prevalence of drug-resistant influenza and pneumococcal disease, and related complications in the elderly. The increased susceptibility of diabetes subjects to pneumonia is mainly due to hyperglycemia, poor long-term diabetes control, longer duration of diabetes, decreased immunity, impaired lung function, pulmonary micro angiopathy, increased risk of aspiration and coexisting morbidity. [5] Longer duration of diabetes and poor glycemic control causes a 25-75% increase in the relative risk of pneumoniarelated hospitalizations in diabetes subjects emphasizing the increased importance of immunization in diabetes subjects. [6] The Centers for Disease Control's (CDC's) Advisory Committee on Immunization Practices recommends infl uenza and pneumococcal vaccines for all individuals with diabetes. [7] A recent publication from India addresses the specifi c issue of Pneumococcal vaccination. [8] In this article we review the role of all vaccinations in relation to diabetes. A systematic literature review was done and 52 studies were identifi ed with particular focus on pneumonia and infl uenza vaccinations. Thirty-two Medline indexed studies are referenced along with Immunization Schedules and Morbidity and Mortality Week Reports (MMWR) by the CDC.
PREVALENCE OF INFECTIONS IN DIABETES

Pneumococcal infections
According to the World Health Organization (WHO), the mortality rate due to pneumococcal infections averages 10-20% while it may exceed 50% in high risk groups. [9] It is estimated that people with diabetes are almost three times at higher risk of death due to pneumonia-related complications. [10] Patients with Type 1 diabetes and type 2 diabetes have a 4.4-and 1.2-fold risk of pneumonia-related hospitalizations, respectively. Diabetes subjects with a HbA1c ≥9% are at 60% increased risk of pneumoniarelated hospitalization. It is of interests that even those with an A1c <7% have 22% increased risk in comparison to nondiabetic subjects. [6] There is increasing evidence which suggest that diabetes is one of the most common co-morbidities associated with pneumococcal infections. [11] Diabetes mellitus is an independent risk factor for developing respiratory tract infections due to alterations of host defenses. [10, 12] This is attributed to several factors such as • Poor antibody response • Cell mediated abnormalities • Decreased CD4/CD8 lymphocyte ratios ○ Changes in natural killer cell function ○ Reduced lymphocyte blastogenesis ○ Defects in interleukin-2 function ○ Reduced phagocytic function of monocytes ○ Impaired leukocyte function ○ Predisposition to colonization and pneumonia A recent study shows that patients with preexisting diabetes are at increased risk of community-acquired pneumonia, mainly due to the worsening of existing cardiovascular and kidney disease. [13] Unfortunately there is no published data from India on the prevalence of pneumonia or infl uenza in diabetes patients.
Infl uenza Infection
Mortality due to infl uenza is around 10,000-30,000 annually and people with diabetes are six times more likely to be hospitalized during an infl uenza epidemic [5] report that people with diabetes are six times more likely to be hospitalized during an infl uenza epidemic than those without diabetes, with the mortality varying between 5% and 15%. Evidence that infl uenza can trigger coronary complications, when taken in the context of diabetic subjects, gains more signifi cance since the risk for CVD is already 2-to 4-fold higher in this sub group. [14] Sub group analysis and subsequent studies have shown vaccination to be effi cacious as well as cost-effective in reducing hospital admissions as well as its associated complications.
A prospective study on the effects of a large-scale intervention with infl uenza and 23 valent pneumococcal vaccines in adults aged 65 years or older revealed that in general, vaccination leads to substantial health benefi ts and to a reduction of mortality from all causes in this age group. [15] 
Hepatitis B infection
Hepatitis B virus (HBV) causes a life-threatening liver infection that often leads to chronic liver disease and puts people at high risk of death from cirrhosis of the liver and hepato-cellular carcinoma.
Patients with diabetes are at a 2.1 times increased risk of infection by the HBV than nondiabetics. [16] HBV can be transmitted by medical equipment that is contaminated with blood that is not visible to the unaided eye. [17] Exposures to HBV may occur as a result of assisted monitoring of blood glucose and other procedures involving multi-patient use of fi nger stick devices designed for single-patient use and inadequate disinfection and cleaning of blood glucose monitors between patients. [18] 
R E C O M M E N D AT I O N S F O R VARIOUS VACCINATIONS
Pneumococcal vaccination
There are currently two types of pneumococcal vaccines: Pneumococcal conjugate vaccine (PCV7 and PCV13) and pneumococcal polysaccharide vaccine (PPV). PCV13 is slowly replacing PCV7. [7] The minimum age for administration of PCV and PPV are 6 weeks and 2 years, respectively.
Pneumococcal polysaccharide vaccine
Pneumococcal vaccine is a polyvalent, sterile, liquid vaccine for intramuscular or subcutaneous injection consisting of a mixture of highly purified capsular polysaccharides from the 23 most prevalent or invasive pneumococcal types of Streptococcus pneumoniae. The polyvalent polysaccharide vaccine contains 25 micrograms of purifi ed capsular polysaccharide (0. 
Pneumococcal conjugate vaccine
These are pneumococcal vaccines based on the conjugation of selected capsular polysaccharides to a protein carrier. The conjugate vaccine is supposed to be more effi cient than the polysaccharide vaccine for the prevention of pneumococcal disease in children on account of immunological considerations and based on safety, immunogenicity, and effi cacy trials. Table 1 .
General indications for administration of Pneumococcal Polysaccharide Vaccination (PPV) [23] are enumerated in Table 2 .
Infl uenza vaccination
Influenza vaccine is recommended for all persons aged ≥6 months who do not have any contraindications to vaccination. Trivalent inactivated infl uenza vaccine (TIV) can be used for any person aged ≥6 months, including those with high-risk conditions. Live, attenuated infl uenza vaccine (LAIV) may be used for healthy nonpregnant persons aged 2-49 years. Since the safety or effectiveness of LAIV has not been established in persons with underlying medical conditions like chronic pulmonary (including asthma), cardiovascular (except hypertension) or metabolic (including diabetes mellitus) disorders that confer a higher risk for infl uenza complications, these persons should be vaccinated only with TIV. TIV contains inactivated viruses and thus cannot cause infl uenza. Only subvirion and purifi ed surface antigen preparations of TIV (often referred to as "split" and subunit vaccines, respectively) are available. LAIV is administered intranasally, whereas TIV is administered intramuscularly. [24] ACIP provides yearly guidelines on the prevention and treatment of infl uenza. [24] Pediatric guidelines from the American Academy of Pediatrics (AAP) are consistent with the ACIP recommendations for the 2011-2012 fl u season. [25] According to the ACIP recommendations, vaccinating individuals at high risk before the infl uenza season each year is the most effective measure for reducing the impact of infl uenza. Annual infl uenza vaccination is recommended for all diabetes patients, both type 1 and type 2. On account of the change in circulating strains (antigenic drift) and waning immunity, yearly revaccination is required.
Recommendations by different organizations for Infl uenza vaccination is listed in Table 3 .
General indications for Infl uenza vaccination. [24] is enumerated in Table 4 .
Fluzone high dose is an approved inactivated vaccine for subjects ≥65 years. People in this age group are at highest risk for seasonal infl uenza complications, which may result in hospitalization and death. [24] In clinical studies, Fluzone High-Dose demonstrated an enhanced immune response compared with Fluzone in individuals aged 65 years and older. [29] 
Hepatitis B vaccination
On the basis of available information about HBV risk, morbidity and mortality, available vaccines, age at diagnosis of diabetes, and cost-effectiveness, ACIP 2012 recommends Hepatitis B vaccination for all unvaccinated adults with diabetes younger than 60 years as soon as feasible after injections). Patients with Chronic Kidney Disease including those on hemodialysis should also be vaccinated.
[31]
The vaccine is made from the inactivated (dead) hepatitis B virus. Two single-antigen recombinant hepatitis B vaccines are available. Hepatitis B vaccination usually consists of three doses of vaccine administered intramuscularly at 0, 1, and 6 months. [32] EFFICACY AND SAFETY OF PNEUMOCOCCAL AND 
INFLUENZA VACCINATIONS
The effi cacy and safety of pneumococcal vaccine have been shown in multiple case control studies as ranging from 56% to 81%. [33] In an indirect cohort analysis, [34] the effi cacy of PPV23 was found to be 84% in diabetic patients and the effi cacy of the vaccine did not decline with increasing interval after vaccination. In a retrospective [ 20] a. All persons aged  65 years b. People aged  10 years who have underlying chronic illnesses predisposing them to including, acute nephrotic syndrome chronic cardiac, renal or pulmonary disease, diabetes, etc. c. Tobacco smokers. a. Children  9 years of age who have underlying chronic illnesses.
Canadian
National Advisory Committee on Immunization.
[21]
a. All individuals  65 years of age b. Children  5 years of age and adults who have not previously received pneumococcal vaccines should be vaccinated with Pneu-P-23. Pneu-C-7 is not contraindicated in children  5 years of age with high-risk conditions.
5. The United Kingdom Department of Health. [22] a. All adults over the age of 65 b Children under the age of 5 who have previously had invasive pneumococcal disease. a. Consider all patients over the age of 2 months with increased risk for the following including type I diabetes mellitus, or type 2 diabetes requiring oral hypoglycemic drugs. It does not include diabetes that is diet-controlled. 6. The Geriatric Society of India. [23] Persons aged 50 years and above. diagnosis. Hepatitis B vaccination may be administered at the discretion of the treating clinician to unvaccinated adults with diabetes who are aged ≥60 years. [30] This may be based on likelihood of acquiring the infection at chronic care facilities (assisted blood glucose monitoring, insulin it was observed that adults with type 2 diabetes benefi ted considerably from infl uenza vaccination. Vaccination was associated with a 56% reduction in any complication (95% CI 36-70%), a 54% reduction in hospitalizations (26-71%), and 58% reduction in deaths (13-80%). [39] 
Other vaccinations
According to the Diabetes Public Health Resource of the Centers for Disease Control and Prevention, the following vaccinations are recommended for diabetes patients [40] In the Indian scenario there is a lack of evidence supporting the routine use of all the vaccines listed by CDC. Patients can be counseled on the necessity for Pneumococcal and Infl uenza vaccines, but other vaccines may be considered optional. It is quite obvious that immunization against vaccine preventable infections will be of considerable benefi t in diabetes but their long-term cost effectiveness needs to be evaluated.
Recommended vaccines for diabetes patients [41] are given in Table 5 .
STRATEGIES TO IMPROVE THE RATE OF VACCINATION
Maintaining a diabetes registry, systemic tracking system, and reminder system serve as tools for improvising the acceptance to vaccination. [42] Standing Orders Programs (SOPs) that allow nonphysician medical staff to assess eligibility and administer vaccines without an individualized physician's order are a proven method to increase vaccination rates. [43] However, recent data on their use are not available. [44] Close follow-up by the [19] a. Infl uenza vaccine is recommended annually for all diabetic patients  6 months of age.
1. CDCs ACIP 2011-12 Infl uenza Vaccination Guidelines. [24] a. Routine immunization (annual vaccination) is now recommended for anyone  6 months as soon as vaccine is available. b. Children aged 6 months to 8 years whose vaccination status is unknown or who have never received seasonal infl uenza vaccine before as well as children who did not receive at least 1 dose of infl uenza A Group on Immunization. [26] a. All individuals aged 65 years and over. b. All Aboriginal and Torres Strait Islander peoples aged 15 years and over c. Pregnant women. d. Individuals aged 6 months and over with medical conditions predisposing to severe infl uenza including cardiac disease, chronic respiratory disease, diabetes and other metabolic disorders, renal disease, etc.
Canadian National Advisory
Committee on Immunization for the 2011-2012 Season. [27] a. Infl uenza vaccine may be administered to people of any age who are residents of nursing homes and other chronic care facilities, people  65 years of age and healthy children 6-23 months of age. [32] b. Adults (including pregnant women) and children with the following chronic health conditions are recommended recipients of Infl uenza Vaccine like cardiac or pulmonary disorders, diabetes mellitus and other metabolic diseases, renal disease, etc.
The United Kingdom
Department of Health. [28] a. All individuals aged 65 or over. b. All those aged 6 months or over in a clinical risk group like chronic respiratory disease, heart disease, renal disease, liver disease, diabetes including Type 1 diabetes, Type 2 diabetes requiring insulin or oral hypoglycemic drugs and diet-controlled diabetes. study of a large cohort of 47,365 subjects aged 65 years or older, evidences suggest a vaccine effectiveness of 44% against pneumococcal bacteremia and hence its cost effectiveness for this indication. [35] There are a few studies claiming cost-effectiveness of pneumococcal vaccine and the most notable is a study from the US showing the vaccine to be highly cost effective in preventing pneumococcal bacteremia in people aged >65 years. [36] Pneumococcal vaccine is considered a safe and time-tested vaccine where moderately severe systemic reactions like fever and myalgia are uncommon while severe anaphylactic reactions are extremely rare. [37] The newly licensed conjugate vaccine holds promise as a novel way of improving the immunogenicity of pure polysaccharide antigens and also of polysaccharides converted to T-cell dependent forms by protein conjugation. [38] Literature search reveals statistically signifi cant increase of antibody titer and an increased percentage of B-lymphocytes 1 week after infl uenza vaccination in diabetic subjects marking valid protection against the infl uenza virus. In a nested case-control study conducted during the 1999-2000 infl uenza A epidemic which was part of the Prevention of Infl uenza, Surveillance and Management (PRISMA) study, diabetes treatment team of the subjects especially with those aged ≥65 years would help achieve the vaccination goals in the most vulnerable groups. Communication with the subjects about the need for vaccination and initiatives like educational packages on immunization, etc., will help generate awareness on the importance of immunization. Setting up a vaccine-only clinic as adjunct or making provision for vaccination during routine visits to the clinic and strictly following the ADA and ACIP recommendations, are some of the strategies for effective immunization. According to the ADA position statement, benchmarking organizations and national policy should emphasize guideline implementation strategies for improving the rate of immunization. [45] Successful implementation of standing orders for vaccination and immunization are essential for increasing vaccination rates. Periodic training of the staff accompanied by ongoing assessment of immunization rates, work fl ow, and missed opportunities to immunize patients are critical to sustain and enhance improvements. [46] There should be a detailed plan for the program's infrastructure, key service delivery components and quality assurance. [47] In the Indian clinic set up, the diabetologist, dietitian, diabetes educator, pharmacist, psychologist, and other members of the diabetes care team may take over the responsibility of counseling the patients on the availability and requirement of routine vaccinations. Use of educational material in local language, discussion on vaccination during diabetes education and the use of vaccination cards will boost confi dence among the patients. Some of the strategies that may improve the rate and outcomes of vaccination include:
• Identifi cation of eligible candidates for vaccination.
• Informing the patients and caregivers regarding the benefi ts and risks of the vaccination and documenting the delivery of that information.
• Documenting refusal to take vaccination or presence of a contraindication like allergy to egg, a recent episode of Guillain-Barre syndrome, etc.
• Recording the administration of a vaccine and records of revaccination or postvaccination adverse events.
• Providing a documentation of vaccine administration to subjects like vaccination card with full information regarding the vaccines.
The standing order protocols should be implemented such that the health care professionals should be trained to:
• screen patients who are most likely to benefi t from and identifying those with contraindications to vaccinations • administer vaccines • monitor patients for adverse events.
The standards for adult immunization practice established by the National Coalition for Adult Immunization recommend a standard personal and institutional immunization record to verify the immunization status of patients and thus avoid the risk of inappropriate revaccination. Also a close followup with the vaccinee or his care giver by the treatment team or health care professional is highly benefi cial in minimizing the risk of inappropriate re-vaccinations. The protocols should also aim at implementing a quality assurance process so that the standards of care are maintained.
EXPERIENCE WITH VACCINATION IN INDIA
In India, till date there is lack of consensus or published guidelines on vaccination in diabetes. There are some clinics offering routine pneumococcal and infl uenza vaccinations while other clinics do not recommend any vaccinations. From the available evidence, the two vaccinations which will be of profound clinical benefi t and cost effective in diabetes subjects would be infl uenza and pneumococcal vaccines.
We present experiences with vaccination at two diabetes centers in India-one from south and one from north India.
In a Diabetes Research Center located in Trivandrum, south India, pneumococcal vaccine has been routinely administered to all consenting subjects with diabetes since 2005. Infl uenza vaccination has also been similarly practiced since 2009. During clinic visits, patients and their caregivers, are briefed on the availability of pneumococcal and infl uenza vaccines, its advantages in diabetes and long-term safety and effi cacy. They are also provided with vaccination cards.
Affordability, willingness, and attitude toward the procedure are taken into consideration before vaccinating each subject. On analysis of the electronic data of subjects on regular follow up with the Diabetes Tele Management System (DTMS ® ) at Jothydev's Diabetes and Research Centre JDC, [48] of the 2057 subjects who underwent pneumococcal vaccinations, only 17 reported mild pain and redness at the site of injection which subsided in a day or two with oral paracetamol tablet. A total of 908 patients underwent fl u shots since 2009 and none of them reported any injection side reactions or allergic responses. We found that 73% of the subjects aged >65 years had been administered the vaccine during one of their routine consultation visits. Of the subjects who received the pneumococcal vaccine 23% of the subjects were suffering from various diabetes-related complications like CVD, renal disease, retinopathy, etc. Age, gender, marital status, geographic area, educational level, occupation, type, duration and therapy of diabetes, and co-morbidities did not have a statistically signifi cant effect on vaccination acceptance.
In a diabetes clinic at Kolkata, 1568 patients (duration >5.3 years) with diabetes were vaccinated against pneumonia and fl u till December 15, 2010. The only side effects observed were aches or pain in joints or muscles, fever, local rash, or swollen glands. No severe allergic reactions were reported. Incidence of fl u was drastically less with reduction of symptoms and absenteeism from fl u when compared with the mean event rate as observed in the past 6 years.
SUGGESTED RECOMMENDATIONS FOR VACCINATION IN INDIA
Based on our experience we make some recommendations i. Hypersensitivity to the active substances or to any of the excipients of the vaccine. ii. History of chicken egg allergy particularly when considering fl u shot.
In these patients, chemoprophylaxis with amantadine/rimantadine or immunization using a protocol as reported by Murphy and Strunk need to be considered. [49] According to this protocol, egg-allergic patients with positive skin-test results could be safely administered the infl uenza vaccine through multiple, graded injections. iii. Recent history of Guillain-Barre syndrome within 6 weeks of a previous infl uenza vaccination in the case of fl u shot. [50] iv. In addition, immunization should be postponed in patients with febrile illness or any acute infection.
for the use of pneumococcal and infl uenza vaccinations in patients with diabetes in India.
The suggested criteria for vaccination are listed in Table 6 .
Contraindications to vaccination are listed in Table 7 .
CONCLUSION
Apart from considering conventional micro and macro vascular events as diabetes complications, infections due to infl uenza and pneumococci should also be regarded as having signifi cant public health importance. All clinics where vaccinations are being advocated for diabetes should keep records of it so that effi cacy of the vaccination may be assessed in relation to occurrence of fever, pneumonia, or hospitalization in vaccinated individuals compared with nonvaccinated subjects. Vaccination strategies in diabetes should evolve as part of routine care and a central registry need to be maintained. Long-term studies and research aimed at evaluating the cost-effectiveness of vaccination among diabetes patients in India would provide more evidence and support for the suggested vaccination guidelines.
